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Abstract: Craniomandibular osteopathy (CMO) and calvarial hyperostotic syndrome (CHS) are
proliferative, non-neoplastic disorders affecting the skull bones in young dogs. Different forms of
these hyperostotic disorders have been described in many dog breeds. However, an incompletely
dominant causative variant for CMO affecting splicing of SLC37A2 has been reported so far only in
three Terrier breeds. The purpose of this study was to identify further possible causative genetic
variants associated with CHS in an American Staffordshire Terrier, as well as CMO in seven affected
dogs of different breeds. We investigated their whole-genome sequences (WGS) and filtered variants
using 584 unrelated genomes, which revealed no variants shared across all affected dogs. However,
filtering for private variants of each case separately yielded plausible dominantly inherited candidate
variants in three of the eight cases. In an Australian Terrier, a heterozygous missense variant in the
COL1A1 gene (c.1786G>A; p.(Val596Ile)) was discovered. A pathogenic missense variant in COL1A1
was previously reported in humans with infantile cortical hyperostosis, or Caffey disease, resembling
canine CMO. Furthermore, in a Basset Hound, a heterozygous most likely pathogenic splice site
variant was found in SLC37A2 (c.1446+1G>A), predicted to lead to exon skipping as shown before
in SLC37A2-associated canine CMO of Terriers. Lastly, in a Weimaraner, a heterozygous frameshift
variant in SLC35D1 (c.1021_1024delTCAG; p.(Ser341ArgfsTer22)) might cause CMO due to the critical
role of SLC35D1 in chondrogenesis and skeletal development. Our study indicates allelic and locus
heterogeneity for canine CMO and illustrates the current possibilities and limitations of WGS-based
precision medicine in dogs.
Keywords: whole-genome sequencing; craniomandibular osteopathy; calvarial hyperostotic
syndrome; Caffey disease; infantile cortical hyperostosis; rare disease; SLC37A2; COL1A1; SLC35D1
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1. Introduction
Craniomandibular osteopathy (CMO) in dogs is a common type of a hyperostotic disorder, which
mainly affects the mandible (OMIA 000236-9615). CMO is a developmental orthopedic disorder
described in several dog breeds, and it is clinically equivalent to human infantile cortical hyperostosis,
also known as Caffey disease [1] (OMIM 114000). The clinical signs in human patients appear under 6
months of age and are usually self-regressive. This includes swelling and inflammation of soft tissues,
as well as hyperostosis of the facial bones, especially the mandible [2]. The disease typically follows an
autosomal dominant mode of inheritance with reduced penetrance and has been associated with a
common missense variant (NP_000079.2: p.Arg1014Cys) in the COL1A1 gene [3]. However, genetic
heterogeneity exists because this variant was not observed in some of the human Caffey-affected
patients [3–5]. Furthermore, an autosomal recessive type of Caffey disease was recently described,
reporting a nonsense variant in the AHSG gene that encodes alpha 2-HS glycoprotein involved in the
formation of bone tissue [6].
CMO in dogs was first described in 1958 [7], and since then it has been observed in several
dog breeds including Labrador Retriever, Doberman Pinscher, Great Dane, Boxer, English Bulldog,
West Highland White Terrier, Shetland Sheepdog, Pyrenean Mountain Dog, Bullmastiff, Akita, Pit
Bull Terrier, Airedale Terrier, Scottish Terrier, Cairn Terrier, and German Wirehaired Pointer (OMIA
000236-9615). This proliferative bone disorder is usually seen in young, growing dogs up to 12 months
of age and affects both sexes equally. Clinically it is characterized by a painful swelling of the jaw and
the consequent discomfort signs (e.g., difficulty in opening mouth, salivation, and dysphagia that
might result in malnutrition) [8]. In addition, the inflammation of soft tissues often results in fever
during the bone proliferation phase. The hyperostotic disorder is considered self-limiting, and all
clinical signs usually resolve with time, when the regular bone growth and ossification are complete [7].
Calvarial hyperostotic syndrome (CHS) also belonging to the group of canine hyperostotic disorders
clinically resembles canine craniomandibular osteopathy and is not histopathologically distinguishable
from CMO. Both CHS and CMO may be associated with changes of the long bones, consistent with
hypertrophic osteodystrophy. On the basis of histology, it has been proposed that CMO, calvarial
hyperostosis, and hypertrophic osteodystrophy belong all to the same osteoproliferative or hyperostotic
disorder complex depending on the bones affected [9].
Different modes of inheritance have been reported for canine CMO, suggesting heterogeneity and
distinct breed-specific variants. Padgett and Mostosky [10] showed evidence for a recessive mode of
inheritance in the West Highland White Terriers by retrospective pedigree analysis. In a genome-wide
association study, a splicing variant in the SLC37A2 gene (XM_005619600.3:c.1332C>T) was identified
as causative in West Highland White Terriers, Cairn Terriers, and Scottish Terriers. CMO in these Terrier
breeds is inherited with a dominant mode of inheritance with incomplete penetrance [11]. Recently, a
more complex polygenic inheritance for CMO in German Wirehaired Pointers was suggested using
statistical segregation analysis [12]. Therefore, the understanding of the underlying genetics of canine
hyperostotic disorders might benefit from a precision medicine approach.
Germline genetic variation is a quite frequent causal factor in rare diseases in humans.
Whole-genome sequencing (WGS) is a relatively inexpensive method to determine individual
variation [13]. Precision medicine by using WGS has been proven suitable in recent years to
help diagnose rare diseases in single patients and situations with limited access to patients [14].
The methodology has also been successfully adapted to veterinary medicine. For example, single
dogs showing suspicious inherited disorders were sequenced and compared to hundreds of normal
controls [15], which allowed a precise molecular diagnosis reporting the most likely disease-causing
variants [16–18]. A similar approach has also been successfully applied to cats [19–21]. By applying
short-read WGS as the current gold standard in precision medicine, we aimed to identify further
plausible variants associated with canine hyperostotic disorders such as CMO and CHS to improve the
understanding of the etiology of these rare genetic disorders.
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2. Materials and Methods
2.1. Ethics Statement
All animal experiments were performed according to the local regulations. All animals in this
study were examined with the consent of their owners. Sample collection was approved by the
Cantonal Committee for Animal Experiments (Canton of Bern; permit 75/16).
2.2. Animals
Blood samples from a CHS-affected American Staffordshire Terrier and seven dogs affected by
CMO of seven different breeds (Supplementary Table S1) were collected. Genomic DNA was isolated
from EDTA blood samples using the Maxwell RSC Whole Blood DNA kit (Promega, Dübendorf,
Switzerland). All dogs were diagnosed by respective veterinarians on the basis of clinical signs and
imaging. Skull radiographs of four and CT scan images of two of the CMO-affected dogs were obtained.
2.3. Whole-Genome Resequencing
WGS data of the eight affected dogs were obtained after preparation of a PCR (polymerase
chain reaction)-free fragment library at an average 26× coverage. Fastq-files were mapped to the dog
reference genome assembly CanFam3.1. Single nucleotide and small indel variants were called and
NCBI (National Center for Biotechnology Information) annotation release 105 was used to predict
their functional effects, as described previously [15]. Private variants were identified by comparison
with the variant catalog of 576 publically available dogs of 120 various breeds, as well as 8 wolves
(Supplementary Table S1), provided by the Dog Biomedical Variant Database Consortium (DBVDC) [15].
The description of the sequence variants is in accordance with the recommendations of the Human
Genome Variation Society [22]. Integrative genomics viewer (IGV) [23] was used for visual inspection
and validation of the candidate variants found in the affected dogs’ WGS data.
2.4. Protein and Splice Site Predictions
The Genome Aggregation Database (gnomAD) [24] was searched for corresponding variants in
the human COL1A1, SLC37A2, and SLC35D1 genes. PredictSNP [25] and PROVEAN [26] were used
to predict the biological consequences of the discovered COL1A1 variant on the protein. SpliceRack
tools [27] were used to evaluate the SLC37A2 splice site variant. All references to the canine
COL1A1, SLC37A2, and SLC35D1 genes correspond to the accessions NC_006591.3 (chromosome
9) and NC_006587.3 (chromosome 5) (NCBI accession); NM_001003090.1, XM_005619600.3, and
XM_003434643.2 (mRNA); and NP_001003090.1, XP_005619657.1, and XP_003434691.1 (protein),
respectively. The canine COL1A1 protein has 1460 amino acids compared to the human protein
(NP_000079.2) with 1464 amino acids, from which 98% are identical between dog and human. The
canine SLC37A2 protein has 508 amino acids compared to the human protein (NP_001138762.1) with
501 amino acids, from which 86% are identical between dog and human. The canine SLC35D1 protein
has the same length of 355 amino acids compared to the human protein (NP_055954.1), from which
98% are identical between dog and human. For the multi-species COL1A1 protein alignment, the
following NCBI accession numbers for each species were used: NP_001003090.1 (Canis familiaris),
NP_000079.2 (Homo sapiens), NP_001029211.1 (Bos taurus), NP_031768.2 (Mus musculus), NP_445756.1
(Rattus norvegicus), NP_001011005.1 (Xenopus tropicalis), and NP_954684.1 (Danio rerio).
2.5. Availability of Data and Material
The WGS data of all affected as well as comparison cohort dogs/wolves have been made freely
available at the European Nucleotide Archive (ENA). All ENA accession numbers are given in the
Supplementary Table S1.
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3. Results
3.1. Phenotype
We investigated a CHS-affected American Staffordshire Terrier and seven CMO-affected dogs
of different breeds (Australian Terrier, Basset Hound, Cairn Terrier, Curly Coated Retriever, German
Wirehaired Pointer, Old English Sheepdog, and Weimaraner). The diagnosis was made by veterinarians
observing the typical clinical signs including persistent and sharp pain when opening mouth, painful
swelling of the jaw, fever, and in some cases also severe pain of ulna and radius bones. Age of onset of
the clinical signs ranged from 3 to 7 months of age, and skull radiographs/computed tomographic (CT)
images were available for six of the affected dogs (Supplementary Table S1). The imaging findings of
one dog was consistent with CHS and in four dogs with CMO (Figure 1), in the remaining dog, no
changes were identified on radiographs, but clinical signs were consistent with the diagnosis of CMO.
Due to the self-regressive course of the disorder, the remission of clinical signs appeared in all cases
soon after the diagnosis and symptomatic treatment. On the basis of the previously published gene test,
all eight collected dogs were genotyped negative for the reported CMO-causing variant in SLC37A2
(XM_005619600.3:c.1332C>T) [11]. In addition, for all eight dogs, the region of the SLC37A2 gene
was also manually inspected in IGV to confirm no candidate variants were missed in the functional
annotation and to rule out obvious, large structural variants including copy number variation affecting
this gene.
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Figure 1. Radiographs/computed tomographic (CT) images of the craniomandibular osteopathy 
(CMO)/calvarial hyperostotic syndrome (CHS)-affected dogs. (a) Sagittal and transverse CT images 
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along the mandible (arrowheads). (e) Transverse CT image of a Weimeraner with the arrowheads 
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mandibular corpus. 
3.2. Identification of Private Candidate Variants 
Figure 1. Radiographs/computed tomographic (CT) images of the craniomandibular osteopathy
(CMO)/calvarial hyperostotic syndrome (CHS)-affected dogs. (a) Sagittal and transverse CT images of
an American Staffordshire Terrier showing severe thick ning of the calvarial diploic bone (arrowheads).
(b) Ventrolateral-dorsola eral ob ique and ventrodorsal skull radiographs illustrating a p lisading
perioste l new bone formation along the mandible of a Basset Hound (arrowheads). (c) Open mouth
laterolateral and ventrodorsal view of the skull of a German Wirehaired Pointer showing periosteal
new bone formation along the mandible (arrowheads). (d) Slightly oblique laterolateral view of
the mandible of an Old English Sheepdog showing similar periosteal new bone formation along the
mandible (arrowheads). (e) Transverse CT image of a Weimeraner with the arrowheads pointing towards
the periosteal new bone formation at the ventral and medial aspect of the left mandibular corpus.
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3.2. Identification of Private Candidate Variants
We considered both the autosomal dominant and autosomal recessive modes of inheritance when
analyzing the WGS data. Filtering for private variants present in a homozygous or heterozygous state
in all eight affected dogs and absent in 584 publicly available dog and wolf genomes revealed no
variants shared across all cases. However, filtering for private variants of each of the cases separately
yielded possible dominantly inherited candidate protein-changing variants in three cases (Figures 2–4).
In the remaining five affected dogs, no variants in obvious functional candidate genes were found.
Therefore, we report a catalog of each dog’s private variants (Supplementary Tables S2–S9). The total
number of variants per genome, when compared to the CanFam3.1 reference, ranged from 4.9 million
in the American Staffordshire Terrier to 5.6 million in the Basset Hound (Table 1). After filtering against
the public genomes, on average ≈9200 variants were left with the least count observed in American
Staffordshire Terrier (4582 variants) and the highest in the Basset Hound (13,370 variants), as shown in
Table 1. In total, most of the called variants were located in non-coding intergenic (50.7%) or intronic
(48.3%) regions, whereas on average 64.5 (34–96) protein-changing (0.7%) variants were found in
each genome.
Table 1. Private variants detected in the individual genomes of the 8 affected dogs and absent in the
584 comparison cohort genomes. The table gives total counts of private variants divided into classes on
the basis of their predicted effect. The counts of homozygous/heterozygous genotypes separately are
shown in parentheses.
Affected Dog
Total Variants
in the Whole
Genome
Private Variants after Filtering against 584 Publically Available Genomes
Total Protein-Changing Synonymous Intronic Intergenic
American
Staffordshire
Terrier (CHS)
4,861,208 4582 76 (67/9) 71 (69/2) 2217(1832/385)
2218
(1831/387)
Australian
Terrier (CMO) 5,495,830 13,147 79 (73/6) 30 (24/6)
6527
(6012/515)
6511
(5875/636)
Basset Hound
(CMO) 5,573,559 13,370 96 (87/9) 30 (28/2)
6535
(5917/618)
6709
(6073/636)
Cairn Terrier
(CMO) 5,425,950 7373 55 (45/10) 17 (16/1)
3486
(3066/420)
3815
(3344/471)
Curly Coated
Retriever (CMO) 5,326,349 4960 34 (34/0) 15 (15/0)
2405
(2248/157)
2506
(2260/246)
German
Wirehaired
Pointer (CMO)
5,519,945 11,713 63 (52/11) 28 (25/3) 5706(5137/569)
5916
(5291/625)
Old English
Sheepdog
(CMO)
5,283,629 10,711 59 (52/7) 22 (17/5) 4966(4175/791)
5664
(4558/1106)
Weimaraner
(CMO) 5,201,857 8056 54 (48/6) 26 (21/5)
3859
(3183/676)
4117
(3307/810)
In the CMO-affected Australian Terrier, a missense variant in exon 26 of the alpha 1 chain of type I
collagen (COL1A1) gene was discovered. The detected variant (NM_001003090.1:c.1786G>A) alters the
encoded amino acid residue 596 of COL1A1 (NP_001003090.1:p.(Val596Ile)) with a predicted moderate
impact on the resulting protein (Figure 2). The missense variant affects the triple helix domain of
COL1A1 protein, which typically consists of the invariant Gly-X-Y repeat motif. The amino acid is
conserved across species but the valine to isoleucine substitution was predicted neutral and tolerated
by in silico prediction tools [25,26]. In humans, a similar missense variant has been described in exon 41,
also changing the X residue in the triple repeat motif (Figure 2). There is no non-synonymous variant
in the human COL1A1 coding region reported at the corresponding position in the gnomAD [24].
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7.99 x 10-6) [24]. 
Figure 2. Characterization of the identified functional candidate variant in COL1A1 in the CMO-affected
Australian Terrier. (a) Integrative genomics viewer (IGV) snapshot showing the heterozygous missense
candidate variant (NC_006591.3:g.26191397C>T). (b) Schematic representation of COL1A1 indicating
the c.1786G>A variant location in exon 26 (red) and the previously described human variant (position
with respect to the canine COL1A1) in exon 41 (blue) encoding the triple helix domain. Note that
the canine COL1A1 gene is annotated on the reverse complementary strand. (c) Multispecies protein
alignment of the canine CMO-associated missense variant identified herein (red). (d) Multispecies
protein alignment of the human disease-causing missense variant (blue) [3] with respect to the canine
COL1A1 position.
In the CMO-affected Basset Hound, a splice site variant was found in the solute carrier family 37
member 2 (SLC37A2) gene. This single nucleotide variant (XM_005619600.3:c.1446+1G>A) affects an
evolutionary strongly conserved donor splice site at the beginning of intron 16 and was predicted to
disrupt splicing (Figure 3). The human consensus sequence for the U2-type GT-AG donor splice site
corresponds to a perfect base pairing to the 5′ end of U1 small nuclear RNA [27]. The variant changes
this canonical dinucleotide sequence (Figure 3c) and therefore most likely eliminates the splice site and
leads to skipping of exon 16 and a shortened transcript. One human variant (rs1278346722) alters the
same position of the human SLC37A2 donor splice site as the dog variant; however, the guanine is
exchanged by cytosine (c.1425+1G>C), not by adenine as found here. This human variant is present in
only 2 out of 125,127 patients in a heterozygous state (allele frequency of 7.99 × 10−6) [24].
Lastly, a frameshift variant in the solute carrier family 35 member D1 (SLC35D1) gene
(XM_003434643.2:c.1021_1024delTCAG) was found in a CMO-affected Weimaraner. The schematic
representation indicates that the 4 bp deletion is located in exon 12 and leads to a frameshift affecting
the last 15 amino acids of the SLC35D1 protein, and was predicted to produce a novel 22 amino
acid long C-terminus of SLC35D1 (XP_003434691.1:p.(Ser341ArgfsTer22); Figure 4). There is no
non-synonymous variant in the human SLC35D1 coding region at the corresponding position described
in the gnomAD [24].
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Figure 3. Characterization of the most likely pathogenic variant in SLC37A2 in the CMO-affected
Basset Hound. (a) IGV snapshot s i g the heterozygous splice site candidate variant
(NC_006587.3:g.9 87071C>T). (b) Schematic representation of the SLC37A2 transcript (XM_005619600.3)
including the location of previously identified canine splicing variant at the end of exon 15 [11] (blue),
as well as the newly reported variant at the beginning of intron 16 (red). Note that the SLC37A2
gene is annotated on the reverse complementary strand. (c) Wild type and mutant allele compared to
the human consensus sequence for the U2-type GT-AG donor splice sites [27]. The uppercase letters
indicate exon 16 and lowercase letters intron 16 sequence, whereas the subscript numbers show the
percentage of the respective conserved nucleotide in 186,630 investigated U2-type GT-AG human
5’-splice site motifs. The base at position +1 is a highly conserved G (100%) [27].Genes 2020, 11, 163 8 of 12 
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Figure 4. Characterizati of the identified functional candidate variant in SLC35D1 in the
CMO-affected Weimaraner. (a) IGV snapshot showing the heterozygous frameshift candidate variant
(NC_006587.3:g.43517060_435178063delTCAG), note that the variant description is adapted to the 3’
rule [22]. (b) Schematic representation of the SLC35D1 gene with the variant affecting the last exon.
(c) Comparison of wild type and the predicted mutant C-terminus protein sequence based on cDNA
entry XM_003434643.2. The variant (XP_003434691.1:p.(Ser341ArgfsTer22)) affects the last 15 amino
acids of SLC35D1.
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4. Discussion
On the basis of clinical signs and/or radiography analyses, eight dogs of eight different breeds
were diagnosed with different forms of hyperostotic disorders such as CHS or CMO. Because all eight
affected dogs were homozygous wild type for the previously described variant causing CMO in three
different Terrier breeds [11], whole-genome sequencing of the individual cases was performed to
investigate the underlying genetics.
No variants shared across all 8 affected dogs and absent from 584 publically available genomes
were discovered, which was in accordance with the expectation of several breed-specific types. The
total number of private variants varied greatly between the individual genomes. This might be partially
the consequence of different levels of inbreeding in different breeds, as well as the variable numbers of
breed controls present in the studied dataset [15]. By prioritization of functional candidate genes, three
possible causative variants in COL1A1, SCL37A2, and SLC35D1 were identified when searching for
private variants in the Australian Terrier, the Basset Hound, and the Weimaraner, respectively.
The identified COL1A1:c.1786G>A variant in a CMO-affected Australian Terrier was predicted
to result in a substitution of valine by isoleucine in the triple helix domain of alpha 1 chain of type
I collagen (COL1A1). The structure of connective tissues includes collagens, proteoglycans, and
non-collagenous proteins, as well as enzymes that are necessary for precise extracellular matrix
assembly and degradation. Mutations in genes encoding these distinct components of the matrix
result in similar phenotypes [28]. The triple-helical domain in collagen proteins consists of a Gly-X-Y
repeating motif that is essential for the helix folding [29]. Mutations of the Gly residues lead to more
severe defects such as osteogenesis imperfecta (OMIM 120150, OMIA 002126-9615, OMIA 002127-9913).
On the other hand, substitutions of the X or Y residues result in milder phenotypes and are associated
with Ehlers–Danlos syndrome and Caffey disease (OMIM 120150) [28]. The autosomal dominant form
of infantile cortical hyperostosis in humans (OMIM 114000) is described as a collagenopathy caused by
a single heterozygous missense variant in COL1A1 with incomplete penetrance. This variant affects the
X residue in a triple-helical domain of COL1A1 (Figure 2), but the exact pathogenesis of how it leads to
self-limiting hyperostotic bone lesions is still unclear [3]. Therefore, we speculate that the identified
missense variant in canine COL1A1 might represent a candidate variant of uncertain significance for
CMO in the affected Australian Terrier. However, as the predicted amino acid substitution involves
two chemically similar, hydrophobic amino acids, this result should be considered preliminary and
requires further confirmation.
The detected splice site variant in SLC37A2 is the most likely pathogenic variant for CMO in
the affected Basset Hound. SLC37A2 has been shown to be associated with CMO in Terriers [11].
Belonging to the glucose-phosphate transporter family, it is expressed in bone-related tissues including
bone marrow or osteoclasts. In mice, Slc37a2 was shown to have an important role in osteoclast
differentiation and function [30]. The previously identified synonymous variant causes altered splicing,
resulting in a frameshift and premature stop codon [11]. This likely affects the function of SLC37A2 and
leads to disturbed glucose homeostasis in osteoclasts in the developing bones, potentially explaining
the hyperostosis phenotype of CMO-affected Terriers [11]. The process of splicing consists of the
recognition of exon-intron boundaries by spliceosome complex and the subsequent excision of an
intron and is highly conserved across eukaryotes [31]. Splice sites are classified in four major subtypes
on the basis of components of the spliceosome and the introns’ terminal dinucleotides. The majority of
all human splice sites are the U2-type GT-AG subtype. The highly conserved bases at the first and
second positions of the 5’ motif of U2-type splice sites are G and T (100%) [27]. The herein reported
splice site variant (c.1446+1G>A) detected in a CMO-affected Basset Hound changes this canonical
dinucleotide sequence. Therefore, it most likely disrupts the correct splicing of intron 16.
The SLC35D1 protein-changing variant (c.1021_1024delTCAG) found in a CMO-affected
Weimaraner leads to a frameshift affecting the last 15 amino acids of the SLC35D1 protein. The solute
carrier family 35 member D1 (SLC35D1) gene encodes another nucleotide-sugar transporter, which
has a crucial role in chondroitin sulfate biosynthesis [32]. Chondroitin sulfate chains are an important
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part of cartilage proteoglycans, which are needed for chondrogenesis and skeletal development [33].
Impairment of the proteoglycan synthesis was confirmed in the Slc35d1-knockout mice, which showed
severe chondrodysplasia, including hypoplastic craniofacial bones and extremely short long bones.
The heterozygous Slc35d1+/- mice were phenotypically apparently normal [32]. In humans, autosomal
recessive mutations in SLC35D1 have been described in a rare lethal skeletal dysplasia (OMIM 269250).
On the basis of these comparative data, it seems possible that the canine frameshift variant represents
a likely causative variant for CMO phenotype in the affected Weimaraner. This might be either
due to haploinsufficiency or a dominant negative function of the mutant protein on the residual
wildtype SLC35D1.
The success rate of WGS-based identification of rare disease-causing genes is difficult to determine
because about two-thirds of studied human diseases discover too many credible candidate variants
and in the remaining one-third there are none [13]. Similarly, the comparisons described herein, using
the recently presented DBVDC variant catalog, reduced the ≈5,000,000 variants per genome identified
from WGS to <100 protein-changing variants per genome. Even though the DBVDC variant catalog
is a great resource for identification of potential causal variants in dogs, the numbers of identified
private protein-changing variants per genome are probably overestimated because of the still imperfect
status and annotation of the current CanFam3.1 reference genome, and prioritization of causal variants
remains challenging. For example, there is a gap in the reference assembly in the 5’-region of SLC37A2.
Therefore, sequencing of additional genomes of well-phenotyped breed-matched obligate carriers
and/or affected dogs may help unravel the complete molecular etiology of canine hyperostotic disorders
such as CHS or CMO in the remaining cases by reducing the number of private candidate variants
shared in cases of the same breed. De novo mutations causing autosomal dominant disorders are easier
to identify when parents’ data is available because each individual carries fewer variants that are not
also found in the parents [16]. Unfortunately, for the examined cases in this study, we had no access to
samples of the parents to evaluate the possibility of spontaneously occurring mutations causing the
hyperostotic disorder. Furthermore, analyzing the transcriptome of biopsies or even better relevant
cells from affected tissue by RNAseq methods would be an excellent option to get further insights
into the development of this transient disease phenotype. Despite the availability of the molecular
methods, studying possible temporal and/or cell-specific expression changes remains challenging due
to the practical and ethical limitations of accessing the appropriate samples in privately-owned dogs.
Considering the relatively mild and self-limiting phenotype, some cases may remain undiagnosed,
which together with lower penetrance possibly prevented the identification of further disease-causing
variants. Comparison cohort dogs used for variant filtering were assumed to be non-affected. However,
in light of the fact that the affected individuals with CHS or CMO spontaneously recover, we cannot
rule out the possibility that pathogenic alleles were present in the publically available genomes, which
would obviously limit the power of the WGS-based precision medicine approach.
5. Conclusions
We propose that the novel splicing variant SLC37A2:c.1446+1G>A is most likely pathogenic for
CMO. We report two other candidate causative variants of uncertain significance with less evidence for
pathogenicity in compelling functional candidate genes (COL1A1 and SLC35D1). Further functional
studies are needed to confirm the causality of the described variants, whereas additional genetic
and/or environmental factors might also influence the manifestation of the disorder. In addition, the
detection of structural variants such as larger-sized indels or segmental duplications is strongly limited.
The sensitivity of our variant detection might have been compromised by the presence of gaps in
the reference genome and the employed short-read sequencing technology. Consequently, long-read
sequencing improved reference assembly and annotation quality, and better algorithms for indels
and structural variant calling might overcome these issues in the future. Nevertheless, our study
demonstrates allelic and locus heterogeneity of different forms of canine hyperostotic disorders and
indicates the current possibilities and limitations of precision medicine in dogs.
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